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   The  aim  of  this  study  is  to  report  our  institutional  experience  with  the  use  of  
carboplatin  (carbo)  and  concurrent  cyclosporin  A  (CsA;;  combined  
treatment  abbreviated  as  carbo/CsA)  for  recurrent  epithelial  ovarian  cancer  (EOC)  and  
to  assess  the  efficacy  and  tolerability  of  this  regimen  in  treatment  of  the  treatment  of  
EOC.  The  medical  records  of  patients  diagnosed  with  ovarian  cancer  and  treated  with  
carbo/CsA  from  2000  to  2015  at  Yale  New  Haven  Hospital  were  reviewed.  Histological  
classification  and  staging  were  determined  by  the  World  Health  Organization  and  Ann  
Arbor  systems,  respectively.    Kaplan-­Meier  was  used  to  calculate  progression  free  
survival  (PFS)  and  overall  survival  (OS).  Objective  response  was  defined  by  RECIST  
criteria  on  computerized  tomography  (CT)  or  by  a  >50%  reduction  in  CA-­125.  Statistics  
were  run  using  STATA  software.  Fifty-­four  patients  were  identified  carbo/CsA  and  had  
adequate  documentation  for  analysis.  Patients  received  a  total  of  265  cycles  of  
carbo/CsA  with  a  mean  of  4.9  cycles  per  patient  (range  1-­10).  Mean  PFS  was  7.7  
months  (SD  5.2),  median  5.8  months,  with  a  range  of  1  to  25.4  months.  OR  by  CT  was  
observed  in  7  patients,  objective  response  by  CA-­125  was  observed  in  17  patients.  
There  were  a  total  of  49  patients  with  adequate  data  for  measure  of  objective  response  
by  either  CT  or  CA-­125.  By  either  method,  a  total  of  19  patients  exhibited  objective  
response  for  an  overall  response  rate  of  38.8%.  The  rates  of  OR  were  significantly  
different  in  patients  who  were  platinum  resistant  versus  platinum  sensitive  (p=  0.015).  
Two  of  fifteen  patients  (13.3  %)  defined  as  platinum  resistant  demonstrated  objective  
response  while  17  of  34  patients  (50.0%)  with  platinum-­sensitive  disease  experienced  
objective  response.  Five  patients  (9.3%)  discontinued  therapy  due  to  toxicity.  Most  
common  grade  III  or  IV  toxicities  included  anemia  (7.4%)  and  nausea  and  vomiting  
    
(5.6%)  with  other  grade  III  reactions  including  hypertension,  headache,  and  
pancytopenia,  and  allergic  reaction.  Most  common  low  grade  toxicities  included  
headache  (24%),  nausea  and  vomiting  (18.5%),  and  fatigue  (16.7%).    Both  PFS  and  OS  
were  significantly  higher  in  patients  that  demonstrated  objective  response  on  
carboplatin/CsA  than  those  who  did  not.  There  was  no  significant  association  of,  age  at  
treatment,  number  of  prior  chemotherapeutic  regimens,  histology  or  disease  with  
likelihood  objective  response  or  length  of  PFS.  We  find  that  carbo/CsA  has  activity  in  
platinum  sensitive  patients.  It  also  demonstrates  limited  but  present  activity  in  platinum  
resistant  patients.  The  regimen  was  adequately  tolerated  by  patients  and  revealed  a  
similar  side  effect  profile  to  prior  studies  of  this  regimen.  
   Keywords:  ovarian  neoplasm,  cyclosporin  A,  carboplatin,  platinum  resistance,  
platinum  sensitivity  
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concentration  curve;;  Carbo,  carboplatin;;  CsA,  cyclosporin  A;;  CT,  computerized  
tomography;;  EOC,  epithelial  ovarian  cancer;;  OS,  overall  survival;;  PFS,  progression  free  
survival.  
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Ovarian  cancer  is  the  most  common  cause  of  gynecological  cancer  death  in  the  Western  
world  and  the  second  most  commonly  diagnosed  gynecological  cancer.1  Approximately  
27%  of  gynecologic  cancers  are  of  ovarian  origin,  but  53%  of  all  gynecologic  cancer  
deaths  occur  in  women  who  have  ovarian  cancer.  With  a  mean  age  of  at  diagnosis  of  63  
in  the  US,  five  year  survival  for  the  disease  ranges  from  30  to  39%  overall.  This  rate  has  
remained  stable  despite  development  of  new  treatments.2  The  high  mortality  of  ovarian  
cancer  can  be  attributed  largely  to  late  recognition;;  approximately  seventy-­five  percent  of  
women  will  be  diagnosed  at  stage  III  disease  or  higher.3  
  
Late  diagnosis  is  attributable  to  the  disease’s  late,  nonspecific  clinical  presentation  and  
the  absence  of  effective  screening  measures  in  the  general  population.4,5  Typical  
subacute  clinical  presentation  includes  abdominal  pain,    changes  in  bowel  habits  and  
gastrointestinal  complaints,  or  adnexal  mass.  These  vague  symptoms  can  be  associated  
with  either  early  or  late  stage  and  are  frequently  evaluated  in  the  outpatient  setting,  
where  significant  delay  in  diagnosis,  up  to  one  year  in  11%  of  patients,  may  occur.6,7  
Acute  presentation  may  occur,  with  symptoms  of  bowel  obstruction,  pleural  effusion  or  
deep  venous  thrombosis  (DVT).  This  presentation  is  frequently  the  result  of  bulky  
disease  and  thus  patients  will  already  be  at  advanced  stage.  8  
  
Approximately  95%  of  all  ovarian  cancers  are  epithelial  in  origin  (EOC)  and  thus  the  
primary  focus  of  therapeutic  development.9        The  remaining  5%  of  cancers  develop  from  
the  other  cell-­types  found  in  the  ovary,  including  sex-­cord  stromal,  granulosa,  germ  cell  
or  mixed  cell–type  tumors5.    In  its  healthy  state,  the  ovarian  surface  epithelium  consists  
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of  a  single  layer  of  flat  to  cuboidal  cells  and  lacks  prominent  distinguishing  features.10      
The  pathophysiology  of  EOC  is  poorly  understood,  and  etiology  likely  varies  with  
histological  subtype.  There  are  several  primary  mechanistic  theories  of  pathogenesis  of  
EOC  which  are  not  mutually  exclusive.  The  “incessant  ovulation  hypothesis”  proposes  
that  with  each  episode  of  ovulation,  the  ovarian  epithelium  undergoes  minor  trauma,  and  
is  additionally  exposed  to  estrogen  rich  follicular  fluid  during  repair,  and  that  the  
chronically  repeated  formation  of  these  stromal  epithelial  clefts  and  inclusion  cysts  may  
be  the  source  of  future  neoplasm.11,12    This  theory  is  supported  by  evidence  that  the  risk  
of  ovarian  cancer  increases  linearly  with  number  of  lifetime  menstrual  cycles.11,12  Others  
have  proposed  the  “Gonadotropin  hypothesis.”13  This  theory  posits  that  systemic  
gonadotropins,  such  as    luteinizing  hormones  (LH)  and    follicular  stimulating  hormone  
(FSH)  overstimulate  the  ovarian  epithelium,  leading  to  increased  cellular  proliferation  
and  eventually  to  malignant  transformation.  In  vitro    studies    have  demonstrated  the  
presence  of  gonadotropin  receptors  on  ovarian  epithelium  and  have  shown  higher  
neoplastic  conversion  in  ovarian  epithelial  cells  lines  with  overexpression  FSH  receptors,  
but  the  mechanism  of  the  this  effect  is  not  understood.14,15  The  gonadotropin  hypothesis  
has  been  challenged  however,    by  histological  evaluation  has  demonstrated  that  many  
EOC’s  may  arise  from  the  fallopian  tube,  and  that  frequently  the  origin  cell  of  neoplasm  
in  EOC  is  not  from  the  ovary.16  Further,    This  finding,  paired  with  the  fact  that  an  
increase  in  endometrioid  and  clear  cell  ovarian  cancer  rates  in  women  with  a  history  of  
endometriosis  has  has  led  to  a  modification  of  the  “incessant  ovulation”  theory:  the  
“incessant  menstruation”  hypothesis.  This  theory  posits  that  chronically  refluxing  
menstrual  products  through  patent  fallopian  tubes,  and  the  presumed  inflammatory  
response  that  follows  eventually  leads  to  neoplasm.    In  particular  iron-­containing  tissue  




Risk  and  protective  factors  for  EOC  reflect  these  mechanistic  theories  of  oncogenesis.  
Established  risk  factors  include  age,  and  positive  family  history.  Possible  risk  factors  
include  infertility,  increased  BMI,  and  tobacco  and  alcohol  use.19  Protective  factors  are  
typically  those  that  disrupt  continuous  ovulation.  These  included  lactation,  increasing  
parity  and  incomplete  pregnancies,  lactation,  and  oral  contraceptive  use.20  Additionally,  
surgical  procedures  such  as  TAH,  and  tubal  ligation  confer  weak  protective  benefit  
against  ovarian  neoplasm,  while  prophylactic  bilateral  salpingo-­opherectomy  reduces  
risk  of  ovarian  cancer  by  90%.9  A  subset  of  ovarian  cancers  are  hereditary  in  nature,  
with  7%  of  patients  reporting  a  family  member  with  a  history  of  the  disease.  Most  
heritable  cases  attributable  to  mutations  in  BRCA1  or  BRCA2,  genes  well  known  for  their  
breast  cancer  association.21  EOC  is  diagnosed  variably  across  geographical  and  
socioeconomic  boundaries  which  likely  reflect  both  genetic  and  modifiable  risk  factors.  It  
has  highest  incidence  in  developed  nations,  with  rates  as  high  as  10  per  10,000  women  
in  North  America  and  Europe,  with  lowest  rates  seen  in  Asia  and  Africa.  Increased  rates  
of  ovarian  cancer  are  seen  in  populations  who  migrate  to  areas  of  higher  incidence,  
highlighting  the  effect  of  nongenetic  risk  factors.  Within  North  America,  risk  of  EOC  
disproportionately  affects  Caucasian  women,  with  intermediate  rates    in  Hispanic  
women,  and  lowest  incidence  in  African  American  and  Asian  populations.9    
  
Screening  measures,  including  transvaginal  ultrasound  and  monitoring  of  serum  
biomarkers  markers,  have  shown  no  benefit  when  applied  to  women  without  major  risk  
factors.22,23  CA-­125  is  the  most  commonly  used  serum  biomarker  in  ovarian  cancer.  It  is  
a  glycoprotein  which  is  overexpressed  by  ovarian  cancer  tumor  cells  but  also  is  present  
in  healthy  mullerian  tissue.  Elevation  (levels  >35)    is  typical  in  ovarian  cancer  but  may  
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also  be  seen  during  menstruation  in  premenopausal  women  or    concurrent  with  other  
intra  abdominal  inflammation  This  lack  of  specificity  and  low  positive  predictive  value  in  
low  risk  populations    limits    its  utility  in  the  general  population.24  However,  CA-­125  
remains  a  valuable  way  to  track  response  to  therapy  and  to  monitor  for  disease  
progression.25    CA-­125  can  also  accurately  be  used  as  post-­treatment  surveillance  to  
identify  recurrent  disease.26  While  CA-­125  elevation  detects  recurrence  earlier  than  
awaiting  symptoms  or  imaging  evidence  of  disease,  there  is  some  evidence  that  there  is  
no  survival  benefit  to  defining  and  treating  progression  on  CA-­125  in  the  absence  of  
clinical  symptoms.  27,28  
  
EOC  is  often  initially  suspected  as  a  result  of  clinical  presentation,  by  abnormalities  
found  with  noninvasive  imaging  or  by  elevated  CA-­125.  However,  histological  sampling  
is  required  to  confirm  diagnosis.  This  sample  is  typically  obtained  via  post-­oophorectomy  
tissue  biopsy,  but  may  also  be  acquired  through  paracentesis,  thoracocentesis  or    image  
guided  biopsy.29,30  The  histology  of  EOC  is  heterogeneous,  with  four  primary  histological  
types  of  epithelial  ovarian  cancer:  serous,  endometrioid,  clear  cell,  and  mucinous.  
Serous  histology  accounts  for  70-­80%  of  EOC,  and  its  low  and  high  grade  variants  are  
often  considered  to  be  distinct  entities.1,31  As  mentioned  above,  these  histological  
variants  likely  represent  different  pathophysiological  means  of  development,  and  an  
increasing  number  of  antineoplastic  agents  are  developed  with  the  goal  of  providing  
therapy  to  specific  histological  subtypes.  32  
  
Diagnosis  is  typically  completed  concurrently  with  staging.  EOC  must  be  staged  
surgically.  Operative  procedures  typically  include  total  hysterectomy,  bilateral  salpingo-­
oophorectomy  and  sample  of  pelvic  and  paraaortic  lymph  nodes.  Additional  procedures,  
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including  pelvic  exenteration  and  resection  of  segments  of  small  bowel,  splenectomy,  
and  partial  hepatectomy  may  be  required  in  order  to  optimally  resect  gross  residual  
disease.  Staging  is  broadly  determined  on  a  tumor,  node,  metastasis  (TNM)  system.  
Several  revisions  to  the  international  standards  of  EOC  staging,  the  FIGO  guidelines,    
have  occurred  over  the  last  several  decades,  with  the  most  current  guidelines  presented  
in  2014.33  Those  patients  determined  to  have  initially  unresectable  disease  or  who  are  
poor  surgical  candidates  will  first  undergo  neoadjuvant  platinum-­based  chemotherapy  
prior  to  staging  surgery.  Neoadjuvant  chemotherapy  has  demonstrated  noninferiority  to  
upfront  surgical  staging  in  this  subpopulation  with  some  improvement  in  perisurgical  
morbidity  and  mortality.34,35  In  either  upfront  or  delayed  surgery,  maximal  cytoreduction  
with  initial  staging  procedure  has  shown  a  strong  correlation  to  overall  survival.36  
  
The  standard  of  care  for  EOC  is  well-­established  for  patients  receiving  upfront  surgery,  
regardless  of  histological  subtype  of  disease.37  Maximally  cytoreductive  surgery  and  
staging  is  followed  by  platinum-­based  combination  chemotherapy,  most  commonly  
carboplatin  (carbo)  and  paclitaxel.38–40  Platinum  based  chemotherapies  are  active  in  a  
variety  of  solid  tumors.  They  act  primarily  by  intercalation  of  DNA,  specifically  by  forming  
covalent  bonds  at  nucleophilic  centers  on  purine  bases  of  DNA.  Platinum  allows  for  
cross-­linking  between  two  adjacent  guanines.  This  DNA  damage  activates  the  signal  
transduction  pathways  that  eventually  lead  to  apoptosis.41  Paclitaxel  (trade  name  Taxol)  
is    a  taxane  derived  from  derived  from  the  bark  of  the  pacific  yew  tree  which  acts  by  
stabilizing  and  promoting  microtubule  assembly,  thus  inhibiting  mitosis.42  While  initial  
trials  used  cisplatin  in  these  multi-­drug  chemotherapeutic  regimens,  carboplatin  has  
largely  replaced  cisplatin    in  first-­line  adjuvant  therapy.  Studies  comparing  cisplatin/taxol  
to  carbo/taxol  found  noninferiority  in  progression  free  survival  (PFS)  and  overall  survival  
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(OS)  between  arms,  but  an  improved  toxicity  profile,  including  decreased  nausea  and  
vomiting,  appetite  loss,  and  fatigue    was  demonstrated  in  patients  treated  with  
carboplatin.38,43,44  
  
Encouraging  initial  response  rates  of  60  to  75%  are  seen  with  first-­line  platinum-­based  
chemotherapy.  However  high  relapse  rates,  up  to  80%  in  patients  with  stage  III-­  IV  
disease,  require  a  return  to  therapy.45  Disease  progression  is  assessed  with  multiple  
modalities  in  ovarian  cancer  and  may  be  defined  by  increasing  CA-­125,  increase  in  
gross  disease  on  CT  imaging,  or  via  clinical  progression.  Patients  with  initial  sensitivity  to  
platinum-­based  therapy  will  return  to  a  similar  platinum-­based  regimen  after  relapse.46  
  
Patients  who  fail  to  respond  to  platinum  therapy  or  who  experience  a  disease  relapse  
within  6  months  of  treatment  are  considered  platinum-­resistant.  This  may  occur  with  first  
line  therapy  (sometimes  described  as  “platinum  refractory”  disease).  Platinum  resistance  
tends  to  increase  from  the  initial  rates  25%  to  40%  nonresponse  seen  in  first  line  therapy  
with  subsequent  platinum  therapies.  The  development  of  platinum-­resistant  disease  is  
thought  to  be  multifactorial,  in  part  because  platinum  acts  so  broadly  within  the  cell.  
Studies  have  indicated  that  cancer  cells  may  increase  in  proficiency  of  DNA  repair,  
decreased  cellular  uptake  or  increased  excretion  of  drug,  increased  damage  tolerance  
have  been  proposed.47    In  some  cases,  resistance  may  development  in  a  manner  similar  
to  drug-­resistant  microbes,  with  the  clonal  outgrowth  of    platinum-­resistant  tumor  cells  
initially  present  at  low  levels  that    then  dominate  the  tumor  when  placed  in  a  platinum-­
rich  environment.48  Prognosis  is  poor  in  platinum  resistant  patients.    Second  line  
treatments  are  more  heterogeneous  and  the  benefit  of  any  given  regimen,  with  such  
chemotherapeutic  agents  as  doxorubicin  and  topotecan,  has  a  lower  response  rate  than  
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initial  therapy,  with  10-­30%  overall  response.2    This  subpopulation  historically  has  an  
expected  survival  of  less  than  12  months.49  The  challenge  of  poor  outcomes  in  platinum-­
resistant  and  refractory  EOC  has  made  the  development  and  identification  of  alternative  
second-­line  and  salvage  regimens  a  research  priority.50,51  
  
One  novel  chemotherapeutic  regimen  that  has  been  studied  in  patients  with  platinum-­
resistant  disease  is  the  combination  of  carboplatin  and  cyclosporin  A  (carbo/CsA).  
Cyclosporin  A  is  a  widely  used  immunosuppressant,  perhaps  best  known  for  its  use  in  
the  prevention  of  rejection  in  solid  organ  and  bone  marrow  transplant  recipients  where  it  
to  limit  cellular  immunity  via  inhibition  of  calcineurin,  a  T-­cell  activator,  and  subsequent  
down  regulation  of  T-­cell  activity.52,53  However,  CsA’s  potential  application  in  oncology  
was  pursued  after  in  vitro  studies  on  the  late  1980s  and  and  early  1990s  of  cisplatin-­
resistant  ovarian  cancer  cells  demonstrated  reversed  resistance  to  multiple  
antineoplastic  agents  after  exposure  to  cyclosporine.54,55  Kashani-­  Sabet  and  colleagues  
in  particular  theorized  that  cyclosporin  impacts  multiple  mechanisms  of  resistance.  The  
group  demonstrated  that  thymidylate  synthase  (dTMP)  and  dihydrofolate  reductase,  
enzymes  critical  in  Folate  metabolism  and  dTMP  synthesis,  were  upregulated  in  
platinum  resistant  ovarian  cancer  cell  lines.  They  demonstrated  a  similar  elevation  in  c-­
fos  and  DNA  polymerase  β  gene  expression,  enzymes  perceived  to  act  in  repair  of  
cisplatin-­induced  DNA  damage  through  DNA  synthesis.  They  further  observed  that  with  
exposure  to  cyclosporin,  both  resistance  to  cisplatin  was  reversed  and    concomitant  
downregulation  all  of  these  enzymes  was  observed  after  either  a  one-­time  administration  
of  the  drug  or  weekly  exposures.47    Further  in  vitro  studies  have  attributed  platinum  





These  promising    in  vitro  studies  that  established  the  activity  of  CsA  in  decreasing  drug-­
resistance  led  to  clinical  trials  assessing  its  promise  as  both  a  chemosensitizer  of  
platinum  in  platinum-­sensitive  tumors  and  as  chemomodulator  of  platinum  
resistance.57,58    Chambers  and  colleagues  conducted  several  Phase  I  and  II  trials  to  
assess  efficacy  and  the  feasibility  of  delivering  intraperitoneal  and  intravenous  CsA.  
These  trials  were  conducted  in  conjunction  with  carboplatin  in  vivo  in  research  based  out  
of  Yale  New  Haven  Hospital.59–61  
  
In  an  initial  phase  I  trial,  the  group  administered  carbo/CsA  to  29  patients  with  heavily-­
pretreated  recurrent  EOC,  24  of  whom  were  defined  as  platinum  resistant.  Patients  
received  a  total  of  114  cycles  of  the  regimen  with  escalating  dosing  of  CsA  via  IV.  
Cyclosporin  was  administered  in  an  escalating  loading  dose,  6  to  10  mg/kg,  then  as  a  
continuous  24h  infusion  from  2.5  to  14.5  mg/kg/day.  Carboplatin  was  targeted  to  an  area  
under  the  time  versus  concentration  curve  (AUC)  of  6  mg/mI  x  mm  and  was  not  dose  
escalated.  The  dose  limiting  toxicity  in  this  trial  was  thrombocytopenia,  with  grade  3  to  4  
thrombocytopenia  found  in  35%  of  patients  grade  3  neutropenia,  grade  4  nausea  and  
vomiting  were  seen  in  10%  and  14%  of  patients  respectively.  At  the  maximum  tolerated  
cyclosporin  dose  of  10  mg/kg  a  target  blood  concentration  of  >1  μg/ml  was  determined  
(lower  than  the  >3μg/ml  concentration  of  CsA  is  used  as  a  modulator  of  multidrug  
resistance).  Five  objective  responses  were  achieved,  all  in  platinum  sensitive  patients,  
and  an  additional  5  patients  had  a  75%  or  greater  reduction  in  CA-­125.59  
  
The  Chambers  group  also  conducted  the  sole  clinical  trial  examining  the  effect  of  
carbo/CsA  with  intraperitoneal  rather  than  peripheral  infusion.  In  this  pharmacokinetic  
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and  phase  I  study,  35  patients  were  administered  CsA,  first  alone  then  in  conjunction  
with  intraperitoneal  carboplatin  via  IP  catheter  for  dwell  times  of  four  hours.  At  20  mg  
CsA/kg,  there  was  no  difference  in  mean  blood  CsA  levels  (0.9  microgram/  mL)  or  mean  
IP  CsA  concentrations  (1,000  micrograms/mL)  when  administered  alone  or  with  
carboplatin.  The  most  common  toxicity  was  anemia,  seen  in  66%  of  patients.  Common  
toxicities  at  the  maximum  CsA  dose  delivered  (34.6  mg/kg)  were  anemia,  leukopenia,  
thrombocytopenia,  and  hypertension.  There  were  three  objective  responses  in  this  trial,  
which  lasted  for  three  to  eleven  months.    The  group  considered  the  intraperitoneal  to  
systemic  exposure  favorable  (1/1000)  and  found  that  malignant  ascites  were  particularly  
well-­controlled  with  this  regimen.61  
  
These  findings  formed  the  dosing  regimen  for  a  follow  up  phase  II  study  conducted  by  
the  same  group.  Fifty-­one  patients  with  recurrent  EOC  received  a  total  of  235  cycles  of  
carbo/CsA  via  peripheral  infusion,  as  a  second  to  sixth  line  therapy.  Patients  had  
previously  received  one  to  three  courses  of  platinum-­based  chemotherapy.  Dosing  
followed  the  max  tolerated  doses  of  the  Phase  I:  CsA  was  infused  as  a  loading  dose  of  
10  mg/kg  over  5  h,  followed  by  carboplatin  infused  in  a  one-­time  dose  over  30  mm  at  an  
AUC  of  6  mg/mI  x  mm,  then  a  24-­h  continuous  infusion  of  11.6  mg/kg  CsA.  Eight  
patients  received  more  than  six  cycles  every  28  days,  thirty-­four  patients  received  three  
to  six  cycles;;  and  nine  patients  received  only  one  or  two  cycles.  Thirty-­eight  patients  
were  evaluable  for  objective  response,  and  in  an  additional  nine  patients,  CA-­125  was  
the  only  marker  of  response.  Four  patients  had  no  marker  of  disease.  Of  those  patients  
who  could  be  evaluated,  74%  were  platinum  resistant.  There  were  nine  objective  
responses.  Platinum  resistant  patients  demonstrated  a  14%  response  rate,  and  in  
platinum-­sensitive  patients  there  was  a  50%  response  rate.  No  responses  were  seen  in  
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patients  who  had  only  received  one  to  to  two  cycles.  Patient  maintained  stable  disease  
for  three  to  nineteen  months.  The  regimen  was  well  tolerated,  with  the  most  common  
grade  III  to  IV  toxicities  seen  were  thrombocytopenia  (22%)  and  hypertension  (18%).  60    
     
More  recent  Phase  II  trials  conducted  by  Morgan  and  colleagues  have  have  shown  
mixed  results.58,62,63  Their  group  assessed  Carboplatin/CsA  in  a  small  phase  II  trial  in  
platinum-­resistant  EOC  patients.62      Dosing  was  lower  than  the  Chambers  studies:  CsA  
was  begun  as  an  IV  loading  dose  of  6  mg/kg  over  two  hours.  A  continuous  infusion  of  9  
mg/kg  of  CsA  over  24  hours  was  then  delivered.59,60  Carboplatin  dosage  was  initiated  at  
an  AUC  of  4  between  cyclosporin  infusions  with  an  increase  of  1  AUC  available  if  the  no  
grade  3  to  4  toxicities  developed.  Twenty-­three  patients  were  enrolled  and  received  a  
total  of  58  courses  of  carbo/CsA.  There  was  modest  partial  reversal  of  resistance  
observed,  with  only  one  case  of  objective  response  and  seven  cases  of  disease  
stabilization  for  a  median  of  4.9  months.  This  result  was  in  contrast  to  in  vitro  findings  in  
the  same  manuscript,  which  replicated  earlier  findings  that  CsA  reversed  platinum  
resistance  in  clonogenic  assays.62    
  
A  second  phase  II  trial  conducted  by  Morgan  and  colleagues  evaluated  the  combination  
of  carboplatin/CsA  with  the  addition  alpha-­interferon  with  results  indicating  inadequate  
reversal  of  clinical  resistance  in  patients  with  platinum  refractory  ovarian  cancer.63    
Alpha-­interferon  was  added  in  this  study  as  it  had  demonstrated  some  chemomodulatory  
activity  previously  both  in  conjunction  with    cisplatin  and  as  a  single  agent.64,65    In  this  
study,  31  patients,  19  of  whom  had  platinum-­resistant  disease,  received  a  total  of  86  
courses  of  carbo/CsA/alpha-­interferon.  Three  patients  (10%)  experienced  partial  
response,  while  an  additional  nine  patients  maintained  stable  disease.  Grade  III  toxicities  
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included  myelosuppression,  hypertension,  and  headache.    Dosing  was  the  same  at  their  
2003  study,  and  while  lower  than  dosing  in  the  Chambers  trial,  the  group  found  that  
blood  levels  >1µm/mL  CsA  were  attained,  the  level  determined  to  reverse  platinum  
resistance  in  in  vitro  studies.  Morgan  and  colleagues  suggested  that  perhaps  longer  CsA  
exposures  may  increase  efficacy  of  the  regimen  but  the  prospect  of  significant  toxicities  
made  increasing  dosage  infeasible.  The  combined  results  of  these  two  studies  led  the  
Morgan  group  to  conclude  that  carbo/CsA  did  not  demonstrate  adequate  clinical  benefit  
to  warrant  further  study.58,62  
  
The  combination  of  carboplatin  and  cyclosporin  A  has  been  used  at  Yale  since  the  
1990s  and  continues  to  be  a  treatment  option  in  selected  patients  as  late-­line  therapy.  
This  practice  continues  despite  the  findings  described  by  Morgan  and  colleagues  due  to  
the  promising  result  of  the  Chambers  group  at  Yale  New  Haven  Hospital  and  due  to  
continued  anecdotal  tolerability  and  response  the  patient  cohort  assessed  in  this  review.  
Our  institutional  experience  with  this  regimen  has  not  yet  been  shared  in  the  literature,  
and  to  our  knowledge  there  have  been  no  retrospective  reviews  of  use  of  this  regimen  at  
other  institutions.    We  hypothesize  that  we  will  see  response  rates  similar  to  those  
demonstrated  by  the  Chambers  group,  given  that  these  studies  were  conducted  at  the  
same  institution  and  with  similar  protocols  to  the  current  sample.60  We  describe  these  
outcomes  to  help  to  further  understand  the  efficacy  of  carbo/CsA  in  the  treatment  of  
recurrent  ovarian  cancer,  to  evaluate  its  tolerability,  and  to  assess  what  patient  






Materials  and  Methods  
  
Chart  Review  Strategy  
A  retrospective  chart  review  was  performed  of  patients  managed  at  Yale  New  Haven  
Hospital  from  January  1995  until  February  2015  who  were  diagnosed  with  ovarian  
cancer  and  who  were  treated  with  carboplatin/CsA  at  any  point  in  their  therapy.  This  
project  has  received  approval  from  Yale’s  institutional  review  board.  Charts  were  
identified  through  billing  data  records.  Medical  records,  including  patient  demographics,  
date  of  birth,  date  of  diagnosis,  date  of  death  (if  applicable),  pathology  reports,  histology,  
operative  reports,  chemotherapy/radiation  treatment  records,  medical  history  and  other  
relevant  data  regarding  treatment  including  patient  medical  history,  all  medications,  past  
history  of  surgeries,  demographic  data  including  ethnicity,  smoking  and  employment  
history,  pregnancy  history  including  number  of  pregnancies,  outcomes,  and  all  
recurrences  with  dates  and  treatment.    Staging  for  this  used  the  International  Federation  
of  Gynecology  and  Obstetrics  (FIGO)  2000  criteria.    These  data  were  accessed  using  
the  EPIC  electronic  medical  record  system  which  contained  access  to  historic  electronic  
medical  records.  Patient  information  was  deidentified  and  coded  numerically  in  a  
password  protected  electronic  database  on  a  secure  Yale  server.  
  
We  reviewed  prior  studies  of  carboplatin/cyclosporin  A  in  order  to  define  relevant  factors  
for  this  study.60,62  We  divided  chart  review  data  into  the  following  subsections:  patient  
characteristics,  initial  presentation,  treatment  prior  to  carbo/CsA,  carbo/CsA  course,  
treatment  and  survival  following  carbo/CsA.  Within  patient  characteristics  we  sought  the  
following  variables:  patient  date  of  birth,  age  at  initial  diagnosis,  ethnicity,  age  of  onset  of  
menses,  age  of  menopause,  parity,  duration  of  use  of  oral  contraceptive  pills  and  
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hormone  replacement  therapy,  BRCA  status  (if  available).  In  the  initial  presentation  
section,  the  following  variables  were  recorded:  initial  platelets  prior  to  any  intervention,  
initial  CA-­125  prior  to  any  surgical  or  chemotherapeutic  intervention,  date  of  primary  
staging  procedure,  procedure  completed,  if  neoadjuvant  chemotherapy  was  utilized  or  
upfront  surgery  was  completed,  in  cases  of  neoadjuvant  therapy  the  agents  used  and  
number  of  cycles  completed  were  recorded.  Histological  subtype  and  clinical  stage  of  
disease  were  recorded.  Of  note,  in  patients  who  initially  receive  neoadjuvant  
chemotherapy  (NACT),  true  surgical  staging  was  not  attainable  due  to  preemptive  
chemotherapeutic  intervention.  Generally,  patients  who  required  neoadjuvant  
chemotherapy  have  bulky,  unresectable  disease  consistent  with  late  stage  illness.  At  this  
institution,  these  patients  are  typically  documented  clinically  as  being  “stage  X.”    
However,  to  provide  consistency  within  staging,  we  counted  neoadjuvant  chemotherapy  
recipients  to  be  stage  IIIC  or  above,  rather  than  using  “stage  X”  convention  specific  to  
our  institution.  Those  patients  who  received  no  clinical  staging  or  who  did  not  have  
exploratory  laparotomy  prior  to  NACT  we  classified  as  a  stage  IIIC.  For  those  patients  
who  remained  a  clinical  stage  IV  at  the  time  of  staging  surgery  or  who  had  ex-­lap  prior  to  
staging  that  indicated  stage  IV  disease,  stage  IV  was  indicated.    In  the  “treatment  prior  to  
carboplatin/CsA  section”  variables  included:  initial  adjuvant  chemotherapy,  number  of  
cycles,  and  date  of  completion,  all  following  chemotherapies  and  number  of  cycles  were  
recorded,  date  of  last  chemotherapy  completion  prior  to  initiation  of  the  
chemotherapeutic  regimen  of  interest  and  date  of  relapse.  Of  note,  we  considered  
neoadjuvant  therapy  followed  immediately  by  adjuvant  therapy  with  the  same  regimen  
so  be  a  single  course  of  chemotherapy.  Platinum  sensitivity  was  recorded  as  a  binary  
(yes  or  no)  based  on  whether  patients  had  every  progressed  within  6  months  of  
completion  of  treatment  on  any  prior  platinum  chemotherapeutic  regimen.  Additional  
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surgical  procedures  and  history  of  radiation  therapy  were  documented.  During  the  
carbo/CsA  period,  start  and  end  date  of  carbo/CsA  therapy  were  documented,  and  
cycles  on  carbo/CsA.  CA-­125  at  the  beginning,  following  each  cycle  when  available,  at  
the  end  of  therapy  was  recorded.  Where  available,  we  included  CT  imaging  of  disease  
prior  to  and  following  carbo/CsA  therapy.    As  our  set  was  obtained  from  patients-­off  trial  
we  had  variable  documentation  of  CT  evaluation  of  disease  and  CA-­125.  Described  
toxicities  and  severity  of  toxicities  were  recorded.  Toxicity  was  defined  by  the  the  2010  
Common  Toxicity  Criteria  of  the  National  Cancer  Institute  (CTCAE)  on  a  1-­4  grading  
scale.66    These  ratings  were    based  upon  narrative  documentation  of  toxicities  and  
laboratory  data  within  clinical  notes.  Reason  for  discontinuation  of  carbo/CsA,  date  of  
progression  following  therapy,  ensuing  chemotherapeutic  regimens  with  number  of  




Statistical  analyses  were  completed  using  STATA  13  (Statacorp  LP,  College  Station,  
Texas)  software.  Demographic  statistics  were  calculated  using  mean,  median,  range  
and  standard  deviation.  Comparative  statistics  were  performed  using  student’s  t  test  for  
continuous  variables,  Wilcoxon-­Mann-­Whitney  test  was  used  when  comparing  
nonparametric  continuous  variables  and  Fisher’s  exact  test  was  used  for  categorical  
variables.  Univariate  and  multivariate  linear  and  logistic  regression  were  also  performed.  
Survival  was  determined  by  Kaplan-­Meier  survival  curves.  
  
All  data  collection,  analysis  and  manuscript  preparation  were  conducted  by  this  author  




  Charts  of  88  patients  were  initially  identified  with  a  diagnosis  of  ovarian  cancer  and  a  
record  of  therapy  with  carboplatin  and  cyclosporin.  After  initial  review,  54  patient  charts  
included  adequate  data  available  for  analysis.  Charts  were  excluded  when  key  
information  was  lacking.  This  included:  date  of  death,  cycles  on  carbo/CsA,  relapse  after  
carbo/CsA,  Date  of  disease  progression,  and  notes  documenting  patient  visits  during  
carbo/CsA  regimen.  Charts  that  were  excluded  for  inadequate  information  differed  from  
included  charts  by  date  of  treatment.  Twenty-­three  of  thirty-­four  excluded  patients  were  
treated  before  2006,  when  electronic  medical  records  became  available.  The  remaining  
eleven  excluded  patients  were  either  lost  to  follow  up  or  had  relevant  portions  of  their  
care  completed  at  an  outside  facility  without  accessible  medical  records.  
  
Demographics    
Fifty-­four  patients  were  included  with  a  diagnosis  of  epithelial  ovarian  cancer  who  
received  a  total  of  265  cycles  of  carbo/CsA.  Patient  mean  age  of  diagnosis  was  61.8  
with  a  range  of  33  to  87.    There  were  50  Caucasian  patients,  one  Asian,  one  African  
American  patient  and  two  Hispanic  patients  in  the  sample.  A  subset  of  patients  had  all  or  
some  of  their  basic  obstetric  and  gynecological  history  available.  Forty-­seven  patients  
had  documentation  of  parity,  with  mean  number  of  gestations  at  2.5  (median  2)  range  of  
0  to  11,  with  mean  number  of  live  births  2.0  (median  2)  with  a  range  of  0  to  10.  14.7%  of  
patients  were  nulliparous  and  23.4%  had  never  experienced  a  live  birth.  Age  of  onset  of  
menses  was  available  for  26  patients,  with  a  mean  of  13.1  (range  10  to  17)  and  age  of  
menopause  available  in  37  patients,  with  a  mean  of  49.5  (range  29  to  68).  For  the  24  
patients  who  had  both  menarche  and  menopause  ages  available,  the  mean  years  of  
menses  was  35.9  (range  21  to  55).    History  of  extrinsic  hormone  exposure  was  limited.  
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Thirty-­two  patients  had  documented  history  of  oral  contraceptive  use,  with  eleven  of  
thirty-­two  (34.3%)  patients  reporting  OCP  use.  Eight  of  ten  (80%)  patients  with  
documentation  regarding  hormone  replacement  therapy  had  a  positive  history.  
  
Patient  Disease  characteristics  
Patients  were  skewed  towards  late-­stage  disease.    Fifty-­three  patients  had  adequate  
staging  information,  one  patient  was  listed  as  “unknown”  due  to  having  received  primary  
therapy  at  an  outside  facility.  The  remaining  patients  ranged  from  stage  IIC  through  
Stage  IV  disease  using  FIGO  2000  criteria.  Frequency  breakdown  was  as  follows:  1  
stage  IIC,  2  stage  IIIA,  34  stage  IIIC,  16  stage  IV,  1  unknown.    With  regard  to  histology,  
37  patients  (72.6%)  had  serous  disease.  Of  patients  with  non-­serous  histology,  3  had  
endometrioid  disease,  1  clear  cell,  4  mucinous,  7  were  poorly  differentiated,  and  3  
patients  had  mixed  histology  disease.    
  
Eleven  Patients  had  documented  BRCA  testing  available.  Of  these,  4  were  negative,  4  
were  positive  for  BRCA1  and  3  were  positive  for  BRCA2.  Seven  patients  had  a  history  of  
another  primary  malignancy,  with  6  having  a  history  of  breast  cancer,  and  one  prior  
rectal  cancer.  Two  of  the  patients  with  breast  cancer  were  documented  to  be  BRCA+.  
  
Initial  CA-­125  prior  to  any  chemotherapy  or  surgery  was  available  in  32  patients.  Mean  
initial  CA-­125  was  4604,  median  1030  (range  71.9-­  62756).  Initial  platelets  prior  to  
intervention  were  available  in  34  patients,  with  a  mean  of  421.6,  median  of  39,  with  a  
range  of  156  to  709.  Thirteen  patients  (24.2%)  received  neoadjuvant  chemotherapeutic  
courses.  All  patients  with  neoadjuvant  chemotherapy  courses  received  platinum-­based  
therapies.  One  patient  received  5  cycles  of  neodjuvant  chemotherapy,  while  the  eleven  
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remaining  patients  received  a  typical  6  cycle  course.  When  operative  notes  were  
available,  we  assessed  whether  primary  staging  surgery  had  attained  optimal  
cytoreduction.  38  patients  had  this  data  available,  of  these  26  (68.4  %)  had  optimal  
cytoreduction  while  12  (31.6%)  were  suboptimally  cytoreduced.  
  
By  the  time  patients  were  placed  on  carboplatin/CsA,  they  had  undergone  a  median  of  3  
prior  chemotherapies  (mean  3.2),  with  a  range  of  1  to  9  prior  courses.  Patients  had  
received  from  1  to  4  previous  platinum  based  chemotherapies,  with  a  median  of  one  
prior  regimen  (mean  1.6).  Thirty-­seven  patients  (68.5%)  were  considered  platinum  
sensitive  at  initiation  of  carboplatin/CsA,  and  17  (31.5%)  had  demonstrated  platinum  
resistance.  Thirteen  patients  (24%)  had  undergone  an  interval  debulking  prior  to  carbo/  
CsA.  Two  patients  had  received  radiation  therapy  prior  to  receiving  carbo/CsA.    
Unfortunately,  patient  functional  status  was  only  explicitly  documented  in  four  patients  
and  thus  was  not  included  for  analysis.  
  
When  comparing  platinum  sensitive  to  platinum  resistant  patients,  they  did  not  differ  
significantly  in  terms  of  ethnicity,  age  at  diagnosis,  histology  or  stage  of  disease.  Median  
interval  between  diagnosis  and  initiation  of  carbo/CsA  was  significant  at  p=0.02.    
Platinum  resistant  patients  had  significantly  higher  number  of  courses  of  prior  
chemotherapy  and  number  of  prior  courses  of  platinum  based  chemotherapy  (Fisher’s  
exact  p  <0.0001  and  p=  0.0001respectively).  
  
Carboplatin  Regimen  and  Dosing  
All  patients  on  study  received  carboplatin/CsA  via  port  or  PICC  line  rather  than  
intraperitoneally.  Regimen  was  scheduled  on  a  28  day  cycle  in  53  of  54  patients,  with  a  
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single  remaining  patient  on  a  21  day  cycle.  Initial  planned  course  was  6  cycles  in  all  
patients.  Dosing  information  was  available  in  a  subset  of  patients  but  was  unavailable  in  
the  earliest  treated  patients  in  our  set  due  to  the  absence  of  pharmacy  notes  in  the  EMR  
prior  to  2008.  Forty-­two  patients  received  cyclosporin  at  the  same  dosing  as  described  
by  Chambers  and  colleagues,  with  a  CsA  was  infused  as  a  loading  dose  of  10  mg/kg  
over  5  h,  followed  by  carboplatin  infused  over  30  minutes  or  via  desensitization  
challenge,  followed  by    a  24-­h  continuous  infusion  of  11.6  mg/kg  of  cyclosporin  60.  
Carboplatin  dosing  was  available  in  43  patients.  Planned  carboplatin  dosing  protocols  
varied  between  an  AUC  of  5  and  AUC  of  6.  Thirty-­two  patients  (74.4%)  received  AUC  of  
5,  and  eleven  received  AUC  of  6  (25.6%).  There  were  not  blood  levels  of  either  agent  
available  for  analysis.  As  in  other  studies  of  carbo/CsA,  each  cycle  of  chemotherapy  
required  an  inpatient  visit.  
  
Of  note,  17  patients  of  54  (31.5%)  required  platinum  desensitization  dosing  at  some  
point  during  their  carbo/CsA  regimen  due  to  history  of  carboplatin  reaction,  positive  skin  




A  total  of  265  cycles  was  received  by  54  patients  with  patients  receiving  a  range  of  1  to  
10  cycles,  with  a  mean  of  4.9  cycles  per  patient  (median  5.5).  Objective  response  was  
measured  both  by  CT  and  CA-­125  changes.  As  patients  were  not  included  on  a  clinical  
trial,  they  had  less  frequent  imaging  than  protocoled  patients  in  the  Chambers  and  
Morgan  group  studies  described  above.  Typically,  those  patients  with  imaging  data  
available  had  CT  imaging  prior  to  initiation  of  therapy,  and  underwent  CT  after  
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completion  or  with  suspected  progression  on  treatment.  Initial  CT  was  available  in  47  
patients  prior  to  initiation  of  therapy.  Forty  patients  in  this  group  (85.2%)  demonstrated  
gross  disease  on  CT.  Thirty-­one  patients  had  imaging  following  completion  of  therapy.  
Response  was  defined  by  RECIST  criteria.67  Twenty-­eight  patients  had  both  initial  and  
repeat  CT  imaging  available,  and  5  of  these  patients  did  not  have  gross  disease  initially,  
leaving  23  patients  with  potential  to  evaluate  for  objective  CT  response.  Seven  objective  
responses  (39.4%)  were  seen  in  in  this  population.  An  additional  4  patients  had  no  gross  
disease  at  either  initiation  or  completion  of  therapy.  Remaining  patient  CTs  at  completion  
included  five  patients  with  mixed  response  or  stable  disease,  and  fifteen  patients  
demonstrating  progression.  Three  exams  documenting  progression  did  not  have  
comparison  imaging  before  therapy.    
  
Objective  response  by  CA-­125  was  defined  by  the  guidelines  developed  by  Rustin  and  
colleagues  in  2004  and  used  in  multiple  clinical  trials  of  ovarian  cancer  treatment  since  
that  time.68    CA-­125  reduction  of  50%  or  greater  from  pretreatment  CA-­125  level  and  
with  a  confirmatory  CA125  one  month  following  this  level,  given  an  initial  pretreatment  
CA-­125  at  least  two  times  the  upper  limit  of  normal  and  taken  within  two  weeks  of  
initiating  therapy.69,70  There  were  41  patients  with  CA-­125  at  initiation  who  had  CA-­125  
at  twice  the  upper  limit  of  normal  (>70).  Of  these  patients,  17  (41.4  %)  demonstrated  an  
objective  response  by  these  criteria.  An  additional  three  patients  saw  a  decrease  of  50%  
or  greater  from  initial  CA-­125  which  was  not  sustained  on  repeat  measurement  at  one  
month.  Duration  of  response  during  treatment  varied  from  2  to  8  cycles  in  length,  with  a  
mean  of  4.6  cycles  (median  5,  SD  1.9).  Serial  CA-­125  following  completion  of  treatment  




There  were  a  total  of  49  patients  with  adequate  data  for  measure  of  objective  response  
by  either  CT  or  Ca-­125.  By  either  method,  a  total  of  19  patients  exhibited  objective  
response  for  an  overall  response  rate  of  38.8%.  There  was  both  CA-­125  and  CT  
response  in  5  patients,  the  remaining  two  patients  with  objective  response  on  CT  did  not  
have  CA-­125  levels  available  for  analysis.  The  rates  of  objective  response  were  
significantly  different  in  patients  who  were  platinum  resistant  versus  platinum  sensitive  
(p=  0.015).    Seventeen  of  34  patients  (50.0%)  with  platinum-­sensitive  disease  
experienced  objective  response.  Only  two  of  fifteen  patients  (13.3  %)  defined  as  
platinum  resistant  demonstrated  objective  response.  One  of  these  patients  underwent  6  
cycles  of  carbo/CsA  as  third  line  therapy,  and  experienced  a  partial  objective  response  
on  CT  after  completion  of  treatment  with  a  10.9  month  PFS  before  relapse.    The  second  
platinum-­resistant  responder  had  received  five  prior  chemotherapeutic  regimens.  She  
did  not  have  pretreatment  CT  imaging  but  had  a  documented  Sister  Mary  Joseph  nodule  
at  the  start  of  carbo/CsA.  She  remained  on  therapy  for  10  cycles  with  a  CA-­125  
response  lasting  for  cycles  two  through  ten.  Repeat  CT  at  the  completion  of  her  regimen  
indicated  no  gross  disease  and  she  experienced  a  PFS  of  14.0  months.  
  
Progression  free  survival  was  analyzed  in  those  patients  who  did  not  discontinue  the  
regimen  due  to  toxicity  or  change  in  goals  of  care.71  Progression  was  defined  both  by  
evidence  of  CT  progression,  increase  in  CA-­125,  or  death.  Mean  progression  free  
survival  was  available  across  45  patients.  Mean  PFS  was  7.7  months  (SD  5.2),  median  
5.8  months,  with  a  range  of  1  to  25.4  months.  There  was  no  significant  difference  in  PFS  
in  patients  who  were  platinum  sensitive  (mean  8.3  months)  versus  platinum  resistant  
(mean  6.4  months).  However,  patients  who  experienced  objective  response  experienced  
a  significantly  increased  PFS  than  those  who  did  not  (mean  11.5  versus  5.4  months  
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respectively  and  a  p=  0.0001).  No  difference  in  objective  response,  PFS,  or  OS  was  
seen  in  patients  who  required  desensitization  dosing  while  on  carbo/CsA.  No  significant  
difference  was  observed  in  objective  response  rate,  PFS  or  OS  in  those  patients  who  
were  dosed  with  carboplatin  at  an  AUC  of  5  versus  6.  
  
We  attempted  to  control  for  factors  that  may  impact  therapeutic  response  and  survival,  
although  our  n  was  modest  for  multivariate  statistics.  In  multivariate  linear  regression  
assessing  objective  response,  there  were  no  significant  associations  between  prior  
number  of  previous  chemotherapeutic  regimens,  high  stage  disease,  serous  vs  non-­
serous  histology,  and  age  at  treatment  with  objective  response  rate.  Platinum  resistance  
had  an  odds  ratio  of  0.23  for  objective  response,  however  the  p-­value  was  not  significant  
p=  0.1.  In  multivariate  linear  regression  controlling  for  high  stage  disease,  platinum  
resistance  and  age  at  treatment,  we  found  that  objective  response  was  associated  with  a  
6.7-­month  increase  in  progression  free  survival  (p  <  0.001).  When  controlling  for  these  
factors  as  well  as  optimal  cytoreduction,  objective  response  was  still  associated  with  a  
significantly  increased  overall  survival  of  2.6  years.    
  
Overall  Survival  and  ensuing  treatment  
  
Overall  survival  was  available  in  all  54  patients.  Mean  survival  was  5.9  years  (median  
5.4  yrs,  SD  2.8)  ranging  from  1.6  to  14.5  years.  There  was  a  statistically  significant  
increase  in  overall  survival  in  those  patients  who  experienced  objective  response  while  
undergoing  carboplatin/CsA  therapy.  Mean  overall  survival  in  patients  with  objective  
response  was  7.0  years  and  mean  survival  in  nonresponders  was  4.7  years  (p=  0.0007).  
There  was  no  statistically  significant  difference  in  overall  survival  based  on  whether  
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patients  had  attained  optimal  cytoreduction  with  initial  staging  surgery,  had  received  
neoadjuvant  therapy,  or  had  platinum-­resistant  disease.  
  
Patients  underwent  a  mean  of  3.3  (median  3,  SD  2.5)  ensuing  chemotherapy  regimens  
after  completion  of  carbo/CsA,  with  a  range  of  0  to  11  ensuing  regimens.  Of  these  
ensuing  treatments,  21  patients  underwent  further  platinum-­based  chemotherapy,  with  
17  undergoing  one  course  and  4  undergoing  two  courses.  Of  those  patients  who  
received  further  platinum-­based  therapy,  9  (52.9%)  had  experienced  an  objective  
response  while  on  carbo/CsA.  6  patients  who  were  platinum  resistant  at  the  time  of  
receiving  carbo/CsA  received  further  platinum-­based  chemotherapy,  only  one  of  these  
patients  had  an  objective  response  while  on  carbo/CsA.  
  
Toxicities  
Five  patients  discontinued  the  regimen  due  to  toxicities.  In  these  patients,  the  symptoms  
leading  to  regimen  change  were  allergic  reaction,  hypertension,  hypotension,  
hypothermia  in  one  patient  each,  and  nausea  and  vomiting  in  two  patients.  Two  patients  
died  while  on  therapy.  One  of  these  patients  died  one  month  after  receiving  cycle  5  of  
chemotherapy  due  to  complications  associated  with  disease  progression.  The  second  
patient  died  within  one  month  after  receiving  a  single  cycle  of  carboplatin/CsA  in  the  
context  of  a  hospital  admission  for  small  bowel  obstruction.  Notes  for  neither  patient  
indicated  toxicity  as  a  causal  factor  in  their  demise.  
  
Cardiovascular  toxicities  were  noted  in  seven  patients  (13%).  One  patient  experienced  
grade  1  Atrial  fibrillation.  Three  patients  experienced  hypertension  with  cyclosporin  
infusion,  including  one  grade  3  hypertensive  response.  One  patient  experienced  grade  4  
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hypotension.  This  hypotension  was  unexplained  and  not  accompanied  by  other  evidence  
of  anaphylactic  response.  One  patient  experienced  grade  3  acute  cardiac  syndrome,  
experiencing  an  NSTEMI  with  hemodynamic  stability  while  on  carbo/CsA.  One  complaint  
of  grade  1  palpitations  was  noted.  Renal  complications  were  seen  in  three  patients  
(5.5%),  with  grade  2  AKI  seen  in  one  patient  and  two  patients  with  at  grade  1  AKI.  Seven  
patients  (13%)  experienced  an  allergic  reaction,  including  six  with  grade  2  responses  
and  one  patient  with  a  grade  3  reaction  to  cyclosporine  infusion.  Hematologic  toxicities  
were  documented  in  8  patients  including:  grade  1  pancytopenia  seen  in  a  single  patient,  
one  case  of  grade  2  thrombocytopenia,  grade  3  anemia  was  present  in  four  patients,  
and  grade  1  neutropenia  seen  in  two  patients,  and  grade  2  neutropenia  in  a  single  
patient.  Three  patients  experienced  infection  while  on  protocol,  including  one  grade  4  
urosepsis  episode  requiring  ICU  admission.  The  other  infections  included  a  grade  3  
fever  of  unknown  origin,  and  a  grade  2  port  cellulitis.  
  
Headache  was  the  most  common  toxicity  reported.  Fifteen  patients  (27.8%)  experienced  
headache,  with  one  patient  reporting  grade  3  intractable  headache,  four  patients  with  
grade  2  headaches  and  9  with  grade  one  headache.  With  regard  to  gastrointestinal  
complaints,  Nausea  and  vomiting  was  experienced  by  thirteen  patients  (24.0%),  
including  three  instances  of  grade  3  nausea  and  vomiting.  Grade  1  constipation  was  
noted  in  one  patient.  Neurocognitive  toxicities  were  noted  in  two  patients  (3.7%).  
Confusion  was  noted  in  one  patient,  and  one  episode  of  brief  self-­resolving  hypomania  
was  described  in  a  patient  who  was  taking  dexamethasone  on  protocol.  Nine  patients  
(16.7%)  experienced  grade  1  fatigue.  Remaining  miscellaneous  toxicities  including:  one  
patient  with  grade  2  hypothermia,  one  instance  of  grade  one  mucositis,  and  one  instance  





The  typical  course  of  EOC  is  late  presentation,  with  initial  response  to  platinum-­based  
therapy  followed  by  high  rates  of  relapse  requiring  multiple  chemotherapeutic  regimens,  
and  often  a  conversion  to  platinum  resistant  disease.  The  patients  described  in  this  
study  predominantly  had  late  stage  serous  disease,  with  92.4%  percent  of  patients  
diagnosed  with  stage  IIIC  or  IV  disease.  They  were  also  heavily  pretreated,  with  a  mean  
of  3.2  prior  chemotherapeutic  regimens.    Our  patients  had,  on  average,  received  a  
greater  number  of  prior  chemotherapies  than  those  patients  included  in  clinical  trials  of  
carbo/CsA.  In  the  Chambers  Phase  II  trial,  patients  received  CsA  as  a  second  to  sixth  
line  therapy,  with  a  mean  of  1.8  prior  chemotherapies  and  in  Morgan’s  2007  Phase  II  
trial,  patients  had  a  median  of  2  prior  therapies,  ranging  1-­5  prior  chemotherapeutic  
courses.60,63  While  there  were  no  differences  in  age,  stage  or  histology  we  also  found  
that  platinum-­resistant  patients  in  this  analysis  had  undergone  more  rounds  of  
chemotherapy  and  more  platinum-­containing  regimens  prior  to  starting  on  carbo/CsA.  
Interval  since  diagnosis  also  trended  towards  significance  when  means  were  compared,  
and  was  significant  when  comparing  median  values.  These  differences  were  expected,  
given  the  tendency  of  platinum-­resistance  to  increase  with  platinum  exposure  and  
number  of  prior  therapies.  
  
Our  results  showed  a  higher  objective  response  rate  than  those  found  in  prior  clinical  
trials,  with  a  38%  objective  response  rate,  as  compared  with  prior  response  rates  of  
4.3%  to  24%.  These  earlier  trials  did  not  include  PFS  or  OS  analysis  for  comparison  with  
our  findings.  There  are  three  key  differences  in  our  study  which  may  account  for  in  
increased  objective  response  rate.  Foremost,  the  sample  described  here  is  a  mix  of  both  
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platinum-­sensitive  versus  platinum-­resistant  patients,  in  roughly  a  two  to  one  ratio.  In  
2004,  Morgan  and  colleagues  assessed  outcomes  exclusively  in  platinum  resistant  
patients  and  showed  the  lowest  rates  of  response  a  4.3%.62  Their  2007  study  which  
added  alpha-­interferon  to  the  regimen,  included  both  resistant  and  sensitive  patients  with  
an  overall  response  rate  of  10.0%,  with  the  resistant  group  demonstrating  a  10%  
response  rate  and  the  platinum  sensitive  group  indicating  a  9.1%  response  rate.63  
Chambers  and  colleagues  reported  a  24%  response  rate,  but  subgroup  comparison  
indicates  that  the  higher  response  rate  in  our  cohort  is  driven  by  a  higher  percentage  of  
platinum-­sensitive  patients.  While  Chambers  and  colleagues  included  both  platinum  
sensitive  and  resistant  patients  in  their  cohort  the  percentage  of  platinum  resistance  than  
found  in  our  group  was  lower,  at  74%  versus  30.6%.60    Of  note,  though  Morgan  and  
colleagues  chose  to  exclude  platinum-­sensitive  patients  in  their  2004  study,  there  is  a  
theoretical  benefit  to  using  cyclosporin  in  platinum-­sensitive  patients:  the  same  
mechanisms  which  reverse  platinum-­resistance  in  vitro  may  prevent  the  development  of  
platinum  resistance  and  potential  platinum  sensitivity.62  When  comparing  platinum-­
resistant  patients  only,  we  observed  a  13%  response  rate.  This  was  higher  than  the  
rates  observed  in  the  Morgan  group  trials,  4.7%  in  both  2004  and  10%  in  2007,  and  
comparable  to  the  14%  response  rate  observed  in  Chambers.60,62,63      
  
Another  potential  source  of  variability  in  outcomes  was  that  our  cohort  experienced  
higher  doses  of  both  Carboplatin  and  Cyclosporin  A  than  patients  in  the  Morgan  trials,  
with  cyclosporin  loading  doses  of  6  versus  10  mg/kg,  and  continuous  infusions  of  10  
versus  11.6  mg/kg,  and  a  starting  dose  of  carboplatin  at  4  AUC  rather  than  5.58,62,63    The  
addition  of  alpha-­interferon  to  the  2007  Morgan  phase  II  trial  adds  another  potentially  
contributing  factor  to  the  different  response  we  observed.63  Our  dosing  was  similar  to  the  
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regimen  used  by  developed  the  Chambers  Phase  I  trial.59  We  used  identical  same  
cyclosporin  dosing  in  all  documented  patients.  Intended  doses  of  carboplatin  that  ranged  
between  5  and  6  AUC,  where  the  Chambers  group  began  all  patients  at  an  AUC  of  6.    
  
Criteria  for  objective  response  was  also  defined  differently  across  trials.  In  the  Chambers  
phase  II  trial,  a  75%  reduction  from  CA-­125  start  of  therapy  was  required.60  Their  trial  
was  conducted  prior  to  standardized  guidelines  for  assessing  CA-­125  objective  
response  to  treatment.  Morgan  et  al  defined  objective  response  by  SWOG  criteria  in  
both  phase  II  trials,  requiring  both  evidence  CA-­125  and  CT  response  in  patients.72    We  
defined  our  objective  response  criteria  by  what  valid  measures  could  be  reproducible  
given  available  data  points,  using  RECIST  criteria  for  imaging  and  established  criteria  for  
CA-­125  response.  The  absence  of  a  required  CT  component  in  defining  objective  
response  in  this  sample  may  have  led  to  a  higher  response  rate,  given  that  CA-­125  is  
considered  more  sensitive  than  CT  to  disease  response.    It  is  reassuring,  however,    that  
studies  comparing  RECIST  and  SWOG  criteria  have  shown  comparable  PFS  and  OS  
outcomes  in  other  neoplasms.73  
  
Our  study  showed  objective  response  rates  of  50%  in  platinum-­sensitive  patients  and  a  
mean  PFS  of  8.3  months.  This  is  a  robust  rate  of  response,  comparable  to  the  50%  
response  rate  seen  in  the  Chamber’s  phase  II  trial.60    Standard  second  line  therapy  in  
these  platinum-­sensitive  patients  is  typically  a  return  to  platinum-­based  chemotherapy.  
Response  rates  of  30  to  67%  are  seen  in    platinum-­sensitive    patients  with  recurrent  
disease  receiving  combined  platinum-­based  chemotherapy  in  clinical  trials.74,75  Thus,  the  





The  response  rate  of  13.3%  in  platinum  resistant  disease  is  less  encouraging  than  what  
was  observed  in  platinum  sensitive  patients.  However,  two  significant  responses  were  
documented.  The    response  rate  documented  here    falls    within  the  10-­30%  response  
range    widely  described  in  platinum-­resistant  patients  receiving  standard  second  line  
therapy,  that  is,  a  non-­platinum  single-­agent  chemotherapy    such  as  paclitaxel  or  
doxorubicin.2    We  could  not  find  criteria  contained  within  our  dataset  that  could  explain  
differences  in  platinum-­resistant  patients  who  responded  to  carbo/CsA  versus  who  those  
who  demonstrated  a  lack  of  response.  In  a  larger  dataset  it  would  interesting  to  pursue  
such  characteristics,  including  tumor  genetics  and  more  granular  information  on  patient  
histories  of  platinum  exposure,  response,  and  platinum-­free  intervals  than  was  available  
in  our  set.  
  
To  give  greater  context  to  carbo/CsA’s  efficacy  in  the  heavily  pretreated,  late  stage  
cohort  included  in  the  present  analysis,  we  sought  similar  prior  studies  with  more  
common  salvage  agents.  While  there  is  a  broad  literature  on  late-­line  chemotherapy  
generally,  there  has  been  only  one  prior  study  conducted  in  a  similar  cohort,  with  similar  
methodology  to  our  own  that  was  also  conducted  at  Yale  New  Haven  Hospital.76  
O’Malley  and  colleagues  conducted  a  retrospective  review  of  heavily  pretreated  EOC  
patients  placed  on  weekly  topotecan  therapy  at  this  institution  in  2005.77  Topotecan  is  a  
topoisomerase  I  inhibitor  that  inhibits  DNA  synthesis,  which  is    frequently  used  as  a  
salvage  chemotherapy  in  recurrent  EOC,  however  it  is  typically  administered  on  days  
one  through  five  of  a  28  day  regimen.76,78,79  Response  rates  for  topotecan  in  the  second-­
line  setting  range  from  19%  to  33%  for  platinum-­sensitive  disease    and  12  –18%  for  
platinum-­resistant  disease.80–82    O’Malley  et  al.    assessed  response  to  and  tolerability  of  
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a  weekly  topotecan  regimen  in  35  patients,  16  of  whom  were  platinum  sensitive  and  16  
were  platinum  resistant  or  refractory,  and  3  had  unknown  platinum  status.  Patients  
received  a  total  of  177  cycles  (534  weeks).  Patients  in  this  cohort  had  received  one  to  
four  prior  chemotherapies  regimens,  with  a  median  of  3  prior  chemo  regimens.  They  
were  also  skewed  towards  late  disease,  with  33  of  36  patients  documented  as  stage  III  
or  IV  disease.  These  features  are  similar  to  the  heavily  pretreated,  late  stage  cohort  
found  in  the  present  study.  Response  was  assessed  by  CA-­125  alone.  Twenty-­eight  of  
35  patients  were  evaluable  for  tumor  response.    One  (6%)  of  the  16  patients  with  
platinum-­sensitive  disease  achieved  a  complete  response  and  3  (19%)  achieved  a  
partial  response,  for  a  total  response  rate  of  25%  in  platinum-­sensitive  patients.  In  
platinum  resistant  patients,  one  patient  (6%)  achieved  a  partial  response.    The  median  
response  duration  was  28  weeks  (range,  16  –44  weeks)  for  patients  who  achieved  a  
partial  response.  Stable  disease  was  reported  in  13  (38%)  patients,  including  5  patients  
with  platinum-­resistant/refractory  disease  77.  The  responses  in  the  carbo/CsA  cohort,  a  
50%  response  rate  seen  in  platinum-­sensitive  patients  and  13%  in  platinum-­resistant  
patients,  compares  favorably  with  response  rates  described  in  this  cohort  of  patients  
treated  with  weekly  topotecan.  
  
It  is  of  interest  whether  the  immunomodulatory  effects  of  CsA  would  provide  benefit  in  
the  context  of  a  platinum-­based  regimen  combined  with  another  cytotoxic  agent,  such  as  
paclitaxel.  A  recent  meta-­analysis  of    single  agent  platinum  versus  combined  platinum-­
based  chemotherapy  in  platinum  sensitive  patients  found  significant  improvements  in  
both  PFS  and  OS  for  those  patients  receiving  combined  therapy.74  However,  combined  
therapy  is  associated  with  increased  toxicity  and  worsened  quality  of  life  measures  in  
some  clinical  trials.83,84  The  survival  benefit  of  dual  therapy  provides  a  potentially  
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interesting  future  direction  for  the  assessment  of  cyclosporin’s  value  in  the  treatment  of  
EOC.  It  would  be  interesting  to  evaluate  tolerability  and  survival  in  patients  with  recurrent  
EOC  on  a  combination  of  carboplatin  and  either  paclitaxel  or  doxorubicin  with  
cyclosporin.  In  addition,  it  may  be  reasonable  to  consider  the  use  of  carboplatin/CsA  in  
patients  with  recurrent  EOC  who  are  platinum  sensitive  but  intolerant  to  common  
combined  chemotherapies  such  as  paclitaxel  or  doxorubicin.    
  
When  considering  the  impact  of  our  regimen  on  survival,  we  found  both  significantly  
increased  PFS  and  OS  in  those  patients  who  experienced  objective  responses  while  on  
carboplatin/CsA.  Objective  response  was  associated  with  a  6.7  month  increase  in  
progression  free  survival  when  controlling  for  potentially  contributing  factors.  This  effect  
on  PFS  supports  the  clinical  validity  of  the  objective  responses  documented  in  our  
dataset.  The  significant  increase  in  overall  survival  in  patients  with  objective  response  
was  a  more  notable  finding,  as  late  line  chemotherapy  often  does  not  yield  overall  
survival  benefit.  This  effect  continued  to  be  significant  when  controlling  for  age  at  
treatment,  stage  of  disease,  histology,  history  of  optimal  cytoreduction,  and  neoadjuvant  
chemotherapy.  It  is  possible  that  our  sample  size  limited  this  analysis,  and  it  is  likely  that  
factors  not  available  in  our  dataset,  such  as  patient  functional  status  influenced  
outcomes.  This  effect  does,  however,  support  the  clinical  value  of  objective  response  to  
the  regimen.  
  
There  are  several  subpopulations  specific  to  this  institution  which  are  interesting  to  
consider  when  analyzing  chemotherapeutic  outcomes.  Neoadjuvant  chemotherapy,  
although  it  has  been  demonstrated  to  have  non-­inferiority  to  initial  surgery  in  
appropriately  selected  patients,  is  available  only  through  a  subset  of  oncology  providers,  
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including  Yale  New  Haven  Hospital.  We  have  a  small  sample  size  within  this  study  which  
may  not  have  adequate  power  to  reject  a  null  hypothesis.  However,  our  results,  
regarding  objective  response,  PFS  and  OS  showed  no  significant  differences  between  
outcomes  in  for  those  patients  who  received  neoadjuvant  therapy  or  immediate  surgery  
in  a  population  weighted  towards  late  stage  disease.  These  findings  are  consistent  with  
the  broader  literature  on  survival  outcomes  in  neoadjuvant  chemotherapy  recipients.34  
  
This  sample  also  included  significant  number  of  patients  (31.5%)  who  underwent  
platinum  desensitization  while  receiving  carboplatin  and  cyclosporin.  This  dosing  
regimen  is  used  in  patients  who  are  platinum  sensitive  but  who  experience  platinum  
allergy.  Allergic  reactions  in  platinum  allergic  patients  range  from  mild  infusion-­
associated  pruritic  rash  to  true  anaphylaxis.  While  desensitization  rates  are  promising,  
with  some  studies  showing  success  rates  of  87%,    there  are  a  limited  number  of  sites  
which  offer  desensitization  to  patients.85  Desensitization  dosing  includes  a  period  of  
premedication  with  dexamethasone  and  antihistamines,  followed  by  exponentially  
increasing  platinum  challenge  doses,  beginning  with  a  1/1000  therapeutic  dose  infusion.  
Carboplatin  infusion  is  stopped  if  allergic  response  is  noted.  This  differs  from  a  typical  
one-­time  infusion  of  carboplatin  in  patients  who  have  no  history  of  hypersensitivity.  86,87  
Of  the  17  patients  here  who  underwent  desensitization  in  this  study,  16  (94.1  %)  were  
able  to  continue  the  regimen.  One  patient  was  removed  from  the  regimen  for  allergic  
reaction  although  it  occurred  during  cyclosporin  infusion  prior  to  carboplatin  dosing.  
Fisher’s  exact  tests  showed  no  difference  in  objective  response  rate,  PFS,  or  OS  
between  those  patients  who  required  desensitization  dosing  versus  standard  platinum  
dosing.  We  again  caution  that  our  sample  is  of  modest  size,  so  power  issues  could  
obscure  alterations  in  therapeutic  effects.  
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The  overall  toxicity  profile  of  our  sample  compared  favorably  with  prior  studies  of  the  
carboplatin  and  CsA  regimen  Most  common  grade  III  or  IV  toxicities  included  anemia  
(7.4%)  and  nausea  and  vomiting  (5.6%)  with  other  grade  III  reactions  including  
hypertension,  headache,  and  pancytopenia,  and  allergic  reaction.  This  profile  indicates  a  
lower  incidence  of  similar  serious  side  effects  noted  in  prior  prior  trials.  Most  common  
serious  toxicities  included  thrombocytopenia  (22%  patients),  hypertension  (18%),  
neutropenia  (10%),  anemia  (8%),  leukopenia  (8%)  in  Chambers’  1996  study.  Morgan  
2004  evaluated  toxicities  by  cycle  of  therapy,  finding  grade  3  or  4  granulocytopenia  29%  
courses  of  therapy,  grade  3  anemia  in  6.9%  of  cycles,  and  grade  4  nausea  in  6.9%  of  cases.  
Most  common  low  grade  toxicities  in  this  dataset  included  headache  (24%),  nausea  and  
vomiting  (18.5%),  and  fatigue  (16.7%).  In  prior  studies,  low  grade  toxicities  included  
thrombocytopenia,  neutropenia,  anemia,  nausea  and  headache.    Despite  the  higher  rate  
of  documented  side  effects,  there  were  no  documented  patient  withdrawals  from  these  
clinical  trials.  In  contrast,  this  dataset  had  9.3%  drop  out  rate  for  for  side  effects.    It  is  
possible  that  this  higher  dropout  rate  may  be  attributable  to  a  lower  functional  status  of  
the  patients  in  our  set,  or  if  patient  preferences  and  quality  of  life  concerns  took  higher  
priority  in  an  off-­trial  setting.      
  
Of  note,  this  cohort  of  patients  was  collected  over  fifteen  years  while  various  supportive  
medications  became  more  widely  available.  For  example,  the  availability  of  colony  
stimulators,  such  as  filgrastim  and  its  analogs,  likely  altered  the  frequency  of  toxicities  
related  to  bone  marrow  suppression.  Centrally-­acting  antiemetics,  such  as  ondansetron,  
may  have  altered  incidence  of  intractable  nausea  and  vomiting.    Further,  we  were  limited  
to  including  those  toxicities  described  in  clinical  notes,  and  mild  toxicities  or  minor  
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medical  intervention  may  not  have  been  documented  in  charts  available  to  us  for  the  
current  analysis.  
  
Our  study  contains  several  limitations.  First,  retrospective  research  is  inherently  limited.  
The  patients  included  in  this  study  were  not  randomized  into  groups  designed  to  test  the  
validity  of  our  hypothesis.  All  findings  are  correlative  rather  than  causative.  Additionally,  
the  data  was  not  collected  with  our  current  study  in  mind,  and  may  be  susceptible  to  
biases  due  to  changes  in  data  collecting  methodology  over  time.  We  face  a  particular  
challenge  in  managing  temporal  change  in  our  data  set.  Staging  criteria  has  evolved  
over  the  course  of  time  since  our  patients  were  placed  on  therapy,  with  accepted  staging  
criteria  for  ovarian  cancer  changing  several  times  during  the  time  period  represented  by  
our  data.  We  had  to  attempt  to  approximate  staging  according  to  FIGO  2000  criteria  
based  on  available  operative  notes  and  pathology  reports.  However,  given  the  advanced  
disease  found  in  our  dataset  we  are  confident  that  patients  would  not  having  substantive  
changes  in  their  TNM  classification  with  the  new  changes  in  staging.    Another  limitation  
is  that  the  variables  included  in  the  data  may  not  speak  directly  to  our  hypothesis,  
requiring  the  use  of  approximation  and  extrapolation  for  some  of  the  available  data.  In  
particular,  the  lack  of  documentation  of  patient  functional  status  may  obscure  an  
important  factor  contributing  to  patient  outcomes.  Finally,  this  data  set  is  culled  from  a  
single  institution,  which  may  limit  how  our  findings  can  be  generalized  to  the  broader  
ovarian  cancer  patient  population.  We  believe,  however,  that  the  large  number  of  
patients  and  the  rich  dataset  has  yielded  valuable  information  on  the  use  of  carbo/CSA  




Treatment  options  for  refractory  EOC  have  expanded  since  initial  studies  of  
Carboplatin/CsA.  There  is  currently  rich  activity  in  the  development  of  new  treatment  
modalities  for  patients  suffering  from  recurrent  ovarian  cancer.37,76  Bevacizumab,  which  
targetsthe  VEGF-­receptor  and  has  demonstrated  the  ability  to  shrink  tumors  and  prolong  
PFS  in  ovarian  cancer,  is  just  one  of  the  angiogenesis  pathways  which  may  be  targeted  
and  exploited  to  improve  survival.88  The  folate  receptor,  over-­expressed  in  ovarian  
cancer  and  a  likely  component  of  cyclosporin’s  anti-­resistance  activity  is  also  being  
targeted  by  novel  agents.    Farletuzamab  is  a  humanized  monoclonal  antibody  to  folate  
receptor  alpha  and  is  being  evaluated  in  a  phase  III  placebo  controlled  trial  with  second-­
line  carboplatin–paclitaxel  in  patients  with  platinum-­sensitive  relapsed  ovarian  cancer.89  
Vintafolide  is  a  cytotoxic  agent,  consisting  of  folate  linked  to  a  potent  vinca  alkaloid  
chemotherapy  agent,  desacetylvinblastine  monohydrazide  (DAVLBH).  It  is  currently  
being  evaluated  in  a  phase  III  clinical  trial  for  platinum-­resistant  ovarian  cancer.90    
Several  new  therapies  focus  on  individualized  therapy  for  subsets  of  disease.  Poly(ADP-­
ribose)  polymerase  (PARP)  is  an  enzyme  involved  in  base  excision  repair.  PARP  
inhibitors,  such  as  olaparib,  have  shown  promising  activity  in  BRCA-­mutation  positive  
disease.  BRCA  1  and  2  are  key  for  homologous  recombination.  Mutations  in  BRCA  can  
be  exploited  by  inhibiting  PARP,  and  thereby  by  inhibiting  DNA-­base  excision  repair,  
ultimately  yielding  chromosomal  instability  and  apoptosis.91,92  
  
It  is  interesting  to  consider  that  Cyclosporin  A,  while  functioning  in  a  less  well-­understood  
pathway  in  potentiating  response  to  platinum,  shares  potential  mechanisms  with  some  of  
these  novel  agents.  In  particular,  CsA  is  thought  to  impair  the  folate  pathway  and  
interfere  with  DNA-­  repair.  Given  that  cyclosporin  and    carboplatin  are  both  widely  
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available,  relatively  inexpensive,  and  well-­tolerated,  the  combination  offers  an  intriguing  
option  in  the  armamentarium  for  recurrent  EOC.93,94  
  
Conclusion  
We  reviewed  the  outcomes  and  tolerability  of  carboplatin  and  cyclosporin  therapy  in  54  
patients  with  recurrent,  heavily-­pretreated  and  predominantly  late-­stage  EOC  treated  at  
a  single  institution  over  the  last  ten  years.  Patients  received  a  total  of  265  cycles  of  
carbo/CsA  with  a  mean  of  4.9  cycles  per  patient  (range  1-­10).  Mean  PFS  was  7.7  
months  (SD  5.2),  median  5.8  months,  with  a  range  of  1  to  25.4  months.  By  measure  of  
either  CT  or  Ca-­125  a  total  of  19  patients  exhibited  objective  response  for  an  overall  
response  rate  of  38.8%.  The  rates  of  objective  response  were  significantly  different  in  
patients  who  were  platinum  resistant  versus  platinum  sensitive  (p=  0.015),  with  a  50%  
response  rate  in  platinum-­sensitive  patients  and  13.3%  objective  response  rate  
observed  in  platinum  resistant  patients.  Both  PFS  and  OS  were  significantly  higher  in  
patients  that  demonstrated  objective  response  on  carboplatin/CsA  than  those  who  did  
not.  These  effects  remained  significant  when  controlling  for  age  at  treatment,  number  of  
prior  chemotherapies,  platinum  resistance,  and  disease  stage  and  histology.  Toxicity  
profile  compared  favorably  with  prior  studies  of  carboplatin/CsA,  with  most  common  
grade  3  to  4  side  effects  including  nausea  and  vomiting,  and  anemia.  There  was,  
however,  a  9.3%  drop  out  rate  for  side  effects.    Our  outcomes  are  limited  by  their  
retrospective  nature,  but  have  comparable  findings  to  encouraging  phase  II  trials  of  
carboplatin  and  CsA.  We  consider  the  therapeutic  effects  and  toxicity  profile  
documented  here  adequately  encouraging  for  further  study  of  this  regimen.  Given  that  
cyclosporin  is  widely  available,  relatively  inexpensive,  and  well-­tolerated,  its  combination  
with  carboplatin  offers  a  valid  potential  treatment  option  for  recurrent  epithelial  ovarian  
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cancer,  particularly  for  those  patients  who  may  be  intolerant  of,  or  who  have  already  
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